
PROGRAM

14th International IMBMC Medical Congress



Bio-medical Scientific Cyprus

23 Credits of Continued Medical Education (CME) will be awarded by the CYMA

23 Credits of Continued Professional Development by the CBS

- 19th to 21th of November 2026
- Cultural Center, European University Cyprus

Organized & Supervised by:
Professor Dr Ioannis Patrikios

Organized by:

European University Cyprus | School of Medicine

Co-organized and under the auspices:

CYPRUS MEDICAL ASSOCIATION

Under the auspices:

ΚΥΠΡΙΑΚΗ ΔΗΜΟΚΡΑΤΙΑ ΥΦΥΠΟΥΡΓΕΙΟ ΤΟΥΡΙΣΜΟΥ

REPUBLIC OF CYPRUS DEPUTY MINISTRY OF TOURISM

With the support:

ΑΝΤΑ

Sponsors:

ENERGON · PAPAELLINAS GROUP · ophthalmos Research & Educational Institute · PMI SCIENCE · PROTON MEDICAL · NOVARTIS · CYPRUS CONVENTION BUREAU · CYPRUS conferences & incentives

GEORGIADES & ASSOCIATES Advocates & Legal Consultants · Οδοντοτεχνικό Εργαστήριο Ψηφιακές Τεχνολογίες Χατζηστυλή Θεοδόσης · Pfizer · DELORBIS · PHADISCO · GE HealthCare · ΚΟΑ · Lab Supplies Scientific



ZEISS Axiolab 5


Your Smart Microscope for More Efficient Routine Lab Work

ENERGON

ZEISS

PROGRAM

14th International IMBMC Medical Congress



Bio-medical Scientific Cyprus


23 Credits of Continued Medical Education (CME) will be awarded by the CYMA

23 Credits of Continued Professional Development by the CBS

- 19th to 21th November 2026
- Cultural Center, European University Cyprus

Organized & Supervised by:
Professor Dr Ioannis Patrikios

Under the auspices:


“Some men see things as they
are and say why,
I dream things that never were
and say why not”
George Bernard Shaw (1856- 1950)

ΔΕΙΤΕ ΤΑ ΑΠΟΤΕΛΕΣΜΑΤΑ ΤΗΣ ΕΡΕΥΝΑΣ ΜΑΣ

PMI SCIENCE
PHILIP MORRIS INTERNATIONAL

Δημιουργούμε
ένα μέλλον απαλλαγμένο
από το τσιγάρο

Αναπτύσσουμε εναλλακτικά προϊόντα
χωρίς καύση και αξιολογούμε
τις επιπτώσεις τους στην ατομική
και τη δημόσια υγεία χρησιμοποιώντας
αυστηρές επιστημονικές μεθόδους

Γνωρίστε το PMI Science
pmiscience.com

PMI Science @pmiscience

Το παρόν απευθύνεται μόνο σε επιστήμονες
και επαγγελματίες στον τομέα της υγείας

14th International Multithematic Scientific Bio-Medical Congress (IMBMC)

"Bio-medical Scientific Cyprus"

THURSDAY, 19 NOVEMBER 2026

Program

08:00 – 08:55 **Registration / Coffee**

08:55 – 09:00 **EUC School of Medicine**



MASTERS OF CEREMONY
Short Introduction and Kick-off

Professor Dr. Ioannis Patrikios
Founder and Organizing/Scientific Committee Chairman



In Memoriam: Ada Yonath Nobel Laureate
School of Medicine EUC (1939 – 2026)
"Doctor Honoris Causa"

SESSION I

NEW ENVIRONMENTAL REALITIES AND PUBLIC HEALTH - GLOBAL WARMING
ENVIRONMENTAL AND HABITUAL FACTORS JEOPARDIZE HEALTH: ARE WE REALLY PROTECTED?

Chairs: Prof. Dr. Anastasis Stephanou, Assist. Prof. Dr. Iva Tzvetanova, Prof. Dr. Christos Dimopoulos

09:00 – 09:15 **"Global Warming and its effect on the Occupational Safety & Health of Workers"**



Assoc. Prof. Christos Dimopoulos
Associate Professor of Computer Science & Engineering, European University Cyprus;
Director of Science in Civil Protection, CERIDES

09:15 – 09:30 **"Disaster Risk Reduction in the New Environmental Realities"**



Professor Dr. Giorgos Boustras
Professor in Risk Assessment, European University Cyprus

09:30 – 09:45 **"Nuclear Accidents: Risks, Realities and self-protection"**



Dr. Prodromos Kaplanis
Medical Physics and Radiation Protection Expert Visiting Professor, School of Medicine
European University Cyprus, Frankfurt Branch

09:45 – 10:00 **"Emerging Biohazards and Future Public Health Challenges: A Biosafety Perspective"**



Dr. Timo Kehl
Head, Staff Unit Biological Safety and Research Security German Cancer Research Center (DKFZ)
Heidelberg, Germany

SESSION II

MEDICAL GENETICS, PROTEOMICS, METABOLOMICS AND BIOINFORMATICS AS TOOLS FOR NEW THERAPIES

BLOOD MALIGNANCIES, TOXINS, CHRONIC AND RARE DISEASES AND NOVEL APPROACHES: WHAT ELSE IS YET TO COME?

Chairs: Dr. Pavlos Neophytou, Assoc. Prof. Dr. Charalambos Michaeloudes

10:00 – 10:15 **"The role of genetic disease modifiers in prognosis, therapy and equity of treatment for rare diseases"**



Assoc. Prof. Dr Carsten Werner Lederer
Senior Scientist, Head of Department, Blood Disorder Genetics & Thalassemia,
The Cyprus Institute of Neurology & Genetics (CING)
Assoc. Prof. and Program Coordinator, CING Postgraduate School

10:15 – 10:30 **"Epigenetics in cancer: New mechanistic insights from chromatin proteomics"**



Professor Dr. Antonis Kirmizis
Professor of Epigenetics and Cancer Biology, Department of Biological Sciences
University of Cyprus, Cyprus

10:30 – 10:45 **"Persistent Viral Infection as a Potential Driver of Intestinal Ageing and Tumour Initiation: Insights from Drosophila"**



Dr. Savvas Telonis
Molecular Virology Department, The Cyprus Institute of Neurology & Genetics
Nicosia, Cyprus

10:45 – 11:00 **Sponsored by the Cyprus Biological Society (CBS)**



"Integrating culturomics, multi-omics, and AI-based approaches on the oral and gut microbiomes for the discovery of potential novel probiotics and bioactives"

Professor Dr. Karsten Kristiansen
Laboratory of Integrative Biomedicine, Department of Biology, University of Copenhagen, Denmark and Institute of Metagenomics, BGI-Research, Shenzhen, China
And Institute of Metagenomics, Qingdao-Europe
Advanced Institute for Life Sciences, Qingdao, China

CYPRUS BIOLOGICAL SOCIETY

SESSION III

NEUROLOGY, NEUROGENETICS, NEUROPHYSIOLOGY, NEUROIMMUNOLOGY, NEUROPHARMACOLOGY AND SPINAL CORD INJURY
CHRONIC DISEASES
NEW THERAPEUTIC TOOLS, NOVELTIES AND EMERGING TARGETS, REPURPOSING DRUGS

Chairs: Assoc. Prof. Dr. Dimitris Papadopoulos, Vis. Prof. Apostolos Papalois, Vis. Prof. Tasos Karandreas

11:00 – 11:15 **"Amyloid-Targeting Therapies in Alzheimer's Disease: From Pathophysiological Rationale to Clinical Practice"**



Dr. Costas Michaelides
Consultant Neurologist
American Medical Center/American Heart Institute Cyprus

11:15 – 11:30 **"Vaccines as new Treatment approach for Neurological Autoimmune Diseases"**



Professor Dr. Marios Pantzaris
Senior Consultant Neurologist, Head of Neuroimmunology Department
Cyprus Institute of Neurology and Genetic

11:30 – 11:45 **"Development of novel angiotensin II receptor ligands for neuroprotection, neurorepair and tumour suppression"**



Dr. Patrick Pallier
Reader in Neuroscience, Barts and The London School of Medicine and Dentistry
Centre for Neuroscience, Surgery and Trauma
Queen Mary University of London, The Blizard Institute

11:45 – 12:15 **Lunch Buffet**
POSTER SESSION

SESSION IV

PREVENTIVE CARDIOLOGY, FATS THAT HEAL, FATS THAT KILL, CORONARY ARTERY DISEASE, FOCUS ON TODAY TO ENLIGHTEN THE FUTURE
NAVIGATING LIPID LABYRINTH: KEY QUESTIONS ON LDL AND HDL FOR CARDIOVASCULAR WELLNESS

Chairs: Chairs: Dr. Giorgos Miltiadous, Dr. Fivos Symeonides

12:15 – 12:30 **"Building Cardiovascular Resilience: Lifestyle Medicine and the Prevention of Cardiomyopathy"**



Dr Vicky Zeniou
Cardiology Consultant, Nicosia Polyclinic

12:30 – 12:45 **"Redefining HDL in Residual Cardiovascular Risk: A Nuanced Paradigm Shift in APOA2 and ASCVD Risk Stratification"**



Professor Dr. Kyriakos Kypreos
University of Patras School of Health Sciences, Department of Medicine, Pharmacology laboratory

12:45 – 13:00 **"Lipid Management in Clinical Practice: Achievements and failures in 30 years of Hypolipidemic treatment"**



Dr. Dimitris Richter
Consultant Cardiologist, Euroclinic Hospital, Athens, Greece

SESSION V

INNOVATIONS AND CHALLENGES IN PULMONOLOGY
SLEEP APNEA, ADVANCING COPD AND SEVERE ASTHMA MANAGEMENT, EMERGING THERAPIES FOR INTERSTITIAL LUNG DISEASE, AND ADDRESSING ENVIRONMENTAL INFLUENCES ON LUNG HEALTH

Chairs: Clin. Assist. Prof Dr. Andreas Zachariades, Dr. Panos Hountis, Dr. Tonia Adamides

13:00 – 13:15 **"Sleep Apnea: Beyond the Airway – A Systemic Disease Hidden in Plain Sight"**



Dr. Dimitrios Grassos
NHS Director, Pulmonology Clinic Panarcadian Hospital Tripolis, Certified Somnologist Expert
Vice President of the Greek Association of Pulmonologists. Ε.Πν.Ελ

13:15 – 13:30 **"Frontline Pulmonology in the Emergency Department: Acute Respiratory Disease and the Enduring Challenge of Tuberculosis"**



Dr. Stamatoula Tsikrika
Chest Physician at SOTIRIA Hospital, President of the Union of Pulmonologists of Greece, Scientific Associate of EODY, Board Member of the Mediterranean Institute for Study & Education in the Prevention & Treatment of Infections

13:30 – 13:45 **"Connective Tissue Disease-associated ILD: Current challenges and emerging opportunities"**



Dr. Alexis Papadopoulos
Consultant in Respiratory Medicine, Fellowship in Interstitial Lung Disease
MedCare Clinic, Nicosia, Cyprus

13:45 – 14:00 **"Novel Unified Approaches for the Management of Chronic Obstructive Pulmonary Disease (COPD) and Asthma"**



Professor Dr. Argyris Tzouvelekis
Respiratory Medicine, Professor of Respiratory Medicine University of Patras Greece and Yale University USA

14:00 – 14:20 **KEYNOTE SPEAKER**



Professor Sir Peter Barnes
Professor of Thoracic Medicine, National Heart & Lung Institute

"Accelerated lung ageing as a key mechanism of COPD"

SESSION VI

INTERACTIVE WORKSHOP I

CURRENT TRENDS IN THE MANAGEMENT OF THROMBOSIS AND CARDIOVASCULAR SURGERY

Chairs: Prof. Dr. Miltiadis (Miltos) Matsagkas, Prof. Dr. Konstantinos Toutouzas

14:20 – 14:40 **"Cancer-Associated Arterial Thrombosis: The Next Frontier in Precision Thrombosis in Oncology—The COMPASS-ARTeCAT Breakthrough"**



Professor Dr. Grigoris Gerotziafas (HYBRID)
Director of the CaVITE Research Department (Cancer, Vessels, Biology and Therapeutics), Sorbonne University, Paris and Head of the Center for Cancer–Angiogenesis–Thrombosis and Haemostasis research group Saint Antoine University Hospital AP-HP, Paris France. Professor at the Center for Translational Research and Education, Loyola University Chicago Stritch School of Medicine, and at the Thrombosis and Hemostasis Center, Sechenov University, Moscow, Member of the Russian Academy of Sciences – Thrombosis and Hemostasis Sector

DELORBIS

SESSION COORDINATOR: PROF. DR. MILTIADIS (MILTOS) MATSAGKAS
Professor of Vascular Surgery and Chair, Department of Vascular Surgery, Faculty of Medicine, University of Thessaly, Larissa University Hospital

Chairs: Prof. Dr. Miltiadis (Miltos) Matsagkas, Clin. Assoc. Prof. Dr. Neophytos Zambas, Dr. Konstantinos Vasilas

Format: 10-minute "flash" presentations followed by 10min Interactive discussion

14:45 – 14:55 **"Managing anticoagulant-related bleedings in surgery"**



Professor Dr. Eleni Arnaoutoglou
Professor of Anesthesiology and Chair, Department of Anesthesiology, Faculty of Medicine, University of Thessaly, Larissa University Hospital

14:55 – 15:05 **"Hybrid Aortic Arch Replacement with Frozen Elephant Trunk (FET) Technique: Surgical Considerations, Pearls, and Pitfalls"**



Clinical Professor Dr. Ioannis Tzanavaros
Adult and Pediatric Cardiac Surgeon; Director Cardiac Innovation Center, University of Nicosia Medical School, Apollonion Private Hospital, Nicosia Cyprus

15:05 – 15:15 **"Current trends in the management of Carotid Artery Stenosis"**



Dr. Triantafyllos Giannakopoulos
Consultant Vascular Surgeon Vascular & Endovascular Surgery Lead
Ygia Polyclinic Private Hospital Limassol, Cyprus

15:15 – 15:25 **"Management of Peripheral Artery Disease: where do we stand today?"**



Dr Achilleas Toursidis
Vascular Surgeon, Ygia Polyclinic, Limassol, Cyprus

15:25 – 15:40 **15 Min Interactive Discussion**



LECTURE IN GREEK LANGUAGE WITH SLIDES IN ENGLISH

"Ethical Dilemmas and End of life Decisions in the ICU- A Critical challenge for modern Medicine"

Professor Dr. Ioannis Pnevmatikos
Professor of Intensive Care Medicine, University of Cyprus, Cyprus

16:00 – 16:25 **Break**



UNITED FOR LONG-LASTING† LDL-C CONTROL[1]

LEQVIO is administered every 6 months* and provides effective LDL-C control, supported by 6+ years of data[1,2]

*Two doses a year after the two initial doses. Single subcutaneous injection at the start of treatment, again at 3 months, and thereafter every 6 months.[1]
†LDL-C reduction was maintained during each 6-month dosing interval after 2 initial doses of inclisiran.

LEQVIO® inclisiran

▼ LEQVIO™ **Important note: Before prescribing, consult full prescribing information. Presentation:** Solution for injection: Each pre-filled syringe contains inclisiran sodium equivalent to 284 mg inclisiran in 1.5 ml solution. **Indications:** Indicated in adults with primary hypercholesterolaemia (heterozygous familial and nonfamilial) or mixed dyslipidaemia, as an adjunct to diet: • in combination with a statin or statin with other lipidlowering therapies in patients unable to reach LDLC goals with the maximum tolerated dose of a statin, or • alone or in combination with other lipidlowering therapies in patients who are statinintolerant, or for whom a statin is contraindicated. **Dosage and administration:** Recommended dose: 284 mg administered as a single subcutaneous injection: initially, again at 3 months, followed by every 6 months. **Missed dose:** • If a planned dose is missed by less than 3 months, inclisiran should be administered and dosing continued according to the patient's original schedule • If a planned dose is missed by more than 3 months, a new dosing schedule should be started – inclisiran should be administered initially, again at 3 months, followed by every 6 months. Treatment Transition from PCSK9 Inhibitor: Inclisiran can be administered immediately after the last dose of a monoclonal antibody PCSK9 inhibitor. To maintain LDL-C lowering, it is recommended that inclisiran is administered within 2 weeks after the last dose of a monoclonal antibody PCSK9 inhibitor. **Special populations:** *Renal impairment:* No dose adjustment is necessary for patients with renal impairment (mild, moderate or severe), or end-stage renal disease. *Hepatic impairment:* No dose adjustment is necessary for patients with mild or moderate hepatic impairment. Inclisiran should be used with caution in patients with severe hepatic impairment. *Pediatric patients (below 18 years):* The safety and efficacy of inclisiran have not been established. *Geriatric patients (65 years of age or above):* No dose adjustment is necessary. **Method of administration:** Intended for administration by a healthcare professional. For subcutaneous injection into the abdomen. Leqvio should be inspected visually for particulate matter prior to administration. Each pre-filled syringe is for single use only. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. **Warnings and precautions:** *Hemodialysis:* Hemodialysis should not be performed for at least 72 hours after inclisiran dosing. **Pregnancy, lactation, fertility** *Pregnancy:* No available human data. Animal reproduction studies have not shown risk of increased fetal abnormalities. *Lactation:* Not known if transferred into human milk. A risk to newborns/infants cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from inclisiran therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman. *Fertility:* No human data. No effects on animal fertility. **Adverse drug reactions:** *Common* (≥1/100 to <1/10): Adverse events at the injection site (includes injection site reaction, injection site pain, injection site erythema, and injection site rash). **Interactions:** Not a substrate, inhibitor or inducer of CYP450 enzymes or common drug transporters. Not expected to have clinically significant interactions with other medications. Based on the limited data available, clinically meaningful interactions with atorvastatin, rosuvastatin or other statins are not expected. **Packs and prices:** LEQVIO solution for injection 284mg/1.5ml in pre-filled syringe (with needle guard): €2530.08.

LEQ01/2021

Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to: Novartis Pharma Services Inc., Methonis Tower, 73 Makarios Avenue, 1070 Nicosia, Tel: +357 22 690 690 (Pharmacovigilance Department), Fax: +357 22 315032 or to Pharmaceutical Services, Ministry of Health, CY-1475, www.moh.gov.cy/phs, Tel: +357 22 608 632/661, Fax: +357 22 608 649, by completing the Yellow Card which is available to the public pharmacies or electronically in the website www.kitrinikarta.gov.cy.

References: 1. Leqvio Summary of product characteristics. Novartis. 25.11.2024. **2.** RS Wright, FJ Raal, W Koenig, U Landmesser, LA Leiter, GG Schwartz, A Lesogor, P Maheux, Z Talloczy, S Vikarunnessa, X Zang, KK Ray. ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients. Data presented at the ESC Congress on August 28, 2023.

NOVARTIS

Novartis Pharma Services Inc.
Methonis Tower, 73 Makarios Avenue, 1070 Nicosia, Tel: +357 22 690 690, Fax: +357 22 496 798

LEQ.AD.02.25 CY

OPENING CEREMONY

16:30 – 16:45 SCHOOL OF MEDICINE – VIRTUAL

VOCAL ENSEMBLE
"Amalgamatio Choir"
Conductor: Vasiliki Anastasiou

16:45 – 17:00 WELCOME ADDRESSES

Professor Dr. Ioannis Patrikios
Congress founder and Scientific Organizing Committee Chairman

Associate Professor Dr. Constantinos Tsioutis
Dean, School of Medicine, European University Cyprus

Professor Loizos Symeou
Rector, European University Cyprus

Clinical Professor Dr. Petros Agathaggelou
President, Cyprus Medical Association & Congress Scientific Committee Vice Chairman


Minister of Health
Mr. Neophytos Charalambides



INAUGURATION CEREMONY
Prof. Emmanuelle Charpentier
Nobel Laureate 2020
"Doctor Honoris Causa"

Lab Supplies Scientific

Vyndaqel®
(tafamidis)



Πριν τη συνταγογράφηση συμβουλευθείτε την Περίληψη Χαρακτηριστικών του Προϊόντος που διατίθεται από την εταιρεία.

▼Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακολούθηση. Αυτό θα επιτρέψει το γρήγορο προσδιορισμό νέων πληροφοριών ασφάλειας. Ζητείται από τους επαγγελματίες υγείας να αναφέρουν οποιεσδήποτε πιθανολογούμενες ανεπιθύμητες ενέργειες. Βλ. παράγραφο 4.8 της Περίληψης Χαρακτηριστικών του Προϊόντος για τον τρόπο αναφοράς ανεπιθύμητων ενεργειών.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Pfizer

Pfizer Ελλάς Α.Ε. (Cyprus Branch), Λεωφόρος Αθαλάσσας 26, 2018 Λευκωσία, Κύπρος, Τηλ.: +357 22817690



14th International Multithematic Scientific Bio-Medical Congress (IMBMC)

"Bio-medical Scientific Cyprus"

FRIDAY, 20 NOVEMBER 2026

Program

08:00 – 08:45 **Registration / Coffee**

08:45 – 10:10 (8 min each presentation)

SELECTED ABSTRACTS

Oral Presentations

(The Presenting Authors are underlined)



"Valve-Sparing Aortic Root Replacement: Principles, Surgical Techniques and Clinical Outcomes"

Georgios Theodoros Chountis[1], Panagiotis Hountis[2], Ioannis Paralikas[2], Konstantinos Plestis[3]


[1]European University Cyprus, Nicosia, Cyprus, [2] Department of Cardiothoracic Surgery, Naval and Veterans Hospital, Athens, Greece, [3] Department of Cardiothoracic Surgery, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, USA



"Anticancer and Antioxidant Potential of Plant-Derived Extracts through Modulation of the Kynurenine Pathway"

Evgenia Maria Tsantila[1] Nils Esslinger [2] and Christiana M. Neophytou[1]

[1]Apoptosis and Cancer Chemoresistance Laboratory, Basic and Translational Cancer Research Center, Department of Life Sciences, European University Cyprus, Nicosia 2404, Cyprus; et221233@students.euc.ac.cy, [2] Department of Research and Development, Alpinamed AG, 9306 Freidorf, Switzerland; *Correspondence: c.neophytou@euc.ac.cy; Tel.: +357-22713218



"Breast cancer clonal dynamics under Aromatase inhibition treatment, supported by single-cell DNA sequencing"

Denise G. O'Mahony [1,2,3], Tom Lesluyes [4*], Ina S. Brorson[1,2], Patrik Vernhoff [1,2], Ksenia Sokolova [5,6], Miriam Ragle Aure[1,2], Grethe G. Alnæs[1,2], Rebecca Mae Hoøen[1,2], Arvind Y.M. Sundaram[1], Bjørn-Erik Bertelsen[7], Chandra Theesfeld [5,8], Stephanie B. Geisler [9], Torill Sauer [10,11], Nazli Bahrami [9,11,13], Rahul Parulkar [14], Matthew Fittall [15], Andliena Tahiri [16], Torben Lüders [2,16], Olga Troyanskaya [5,6,8,17], Charles Vaske[18#], Peter Van Loo [4,19,20#], Jürgen Geisler [2,9#], Vessela N. Kristensen[1,2#]

[1]Department of Medical Genetics, Oslo University Hospital, Oslo, Norway, [2] Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo Norway, [3] Department of Biostatistics, the Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus,[4] Cancer Genomics Laboratory, Francis Crick Institute, London, UK, [5] Princeton Precision Health, Princeton, New Jersey USA, [6] Center for Computational Biology, Flatiron Institute, New York, USA, [7] Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway, [8] Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, New Jersey, USA, [9] Department of Oncology, Akershus University Hospital, Lørenskog, Norway, [10] Department of Pathology, Akershus University Hospital, Lørenskog, Norway, [11] Translational Cancer Research Group, Akershus University Hospital, Lørenskog, Norway' [12] Institute of Clinical Medicine, Campus AHUS, University of Oslo, Norway, [13] Department of Breast & Endocrine Surgery, Akershus University Hospital, Lørenskog, Norway.

[14] NantHealth, Culver City, CA, [15] Cancer Services, The Royal Marsden NHS Foundation Trust, London, UK, [16] Department of Clinical Molecular Biology (EpiGen), Akershus University Hospital, Lørenskog, Norway, [17] Department of Computer Science, Princeton University, Princeton, New Jersey, USA, [18] NantOmics, LLC, Santa Cruz, CA, United States, [19] Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, [20] Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
*Equally contributed
#Shared corresponding and last authors



"FlyQTA: Machine Learning-Based Qualitative Assessment of Drosophila Midgut Architecture for Anti-aging and Pro-aging Drug Screening"

Evripides Soteriou[1], Maria Michail[1], Andria Nicolaou[2], Christina Charilaou[1], Katerina Zorba[1], Constantinos S. Pattichis[2], Athos Antoniades[3], Chrysoula Pitsouli[1]
[1]Department of Biological Sciences, University of Cyprus, Nicosia, Cyprus [2] Department of Computer Science, University of Cyprus, Nicosia, Cyprus [3]Stremble, Limassol, Cyprus



Plasma Cell-Free RNA Profiling for Organ Injury in Critical Illness"

Ioannou A[1], Friman ET [1], Daub CO [2,3], Hope D[4], Baillie JK[4], Walsh TS[4], Craven TH[4], Bickmore WA[1], Biddie SC[1,4]
[1] MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom, [2] Department of Medicine Huddinge, Karolinska Institute, Huddinge, Sweden, [3] Science for Life Laboratory, Solna, Sweden, [4] Department of Critical Care, Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, United Kingdom.



"Ten-Year Outcomes After Percutaneous Coronary Intervention of the Left Main Coronary Artery in Patients With Diabetes Mellitus: A Pooled Analysis of Two Randomized Trials"

J. Bresha[1], G. Ndrepepa [2], C. Kuna2, T. Kessler [2,3], I. Hintz[2], P. Justenhoven [2], T. Ibrahim[1], S. Kufner [2], H. Schunkert [2,3], M. Valgimigli [4], G. Richardt [5], K.-L. Laugwitz[1,3], S. Cassese [2], A. Kastrati [2,3], J. Wiebe [2,3]
[1] Medizinische Klinik, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany, [2] Department of Cardiology, Deutsches Herzzentrum München, Technical University of Munich, Munich, Germany, [3] DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany, [4] Division of Cardiology, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland, [5] Department of Cardiology, Asklepios Klinik Bad Oldesloe, Bad Oldesloe, Germany
P. Justenhoven: paul.justenhoven@gmx.de



"The Challenges of STIs in the dermatovenereology of the XXI[st] century"

Mihael Skerlev[1], Andrija Stanimirović [2]
[1]Chair of the HPV Task Force of the European Academy of Dermatology and Venereology (EADV), President of the Croatian STD Society of the Croatian Medical Association, St. Catherine's Special Hospital, Croatian Academy of Medical Sciences, Zagreb, Croatia.
[2] School of Health Studies, University of Zagreb, Zagreb, Croatia and School of Medicine, European University Cyprus, Nicosia, Cyprus



"Delayed Conduction Disturbance After Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: An Emerging Clinical Challenge"

Constantinos Antoniades[1], Georgia Karmioti[1], Nicolaos Eteocleous[1], Ioannis Zittis[1], Kimon Myrianthopoulos[1], Theodoros Christophides[1], Christis Rotos[1], Marios Ioannides[1], Nikolaos Kadoglou[2], Andreas Mitsis[1], Christos Eftychiou[1]
[1] Cardiology Department, Nicosia General Hospital, Nicosia, Cyprus, [2] Medical School, University of Cyprus, Nicosia, Cyprus



"Immune cytolytic activity correlates with tumor microenvironmental aberrations in colorectal cancer"

Stephanie Agioti [1,2], George Georgoulia [1], Ilias Georgakopoulos-Soares[1,3] ,Maria-Ioanna Christodoulou[1], Apostolos Zaravinos[1,2,*]

[1] Department of Life Sciences, School of Sciences, European University Cyprus, Nicosia, Cyprus, [2] Cancer Genetics, Genomics and Systems Biology Laboratory, Basic and Translational Cancer Research Center (BTCRC), Nicosia, Cyprus, [3] Division of Pharmacology and Toxicology, Dell Paediatric Research Institute, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA



"BTK Inhibition and TRIM24 in CD5+ Malignant B Cells"

Charalampos Xanthopoulos[2], Charlotte McDonald [2], Lisa Crawford [3], Vladimir Teif [4], Helen-Ray Jones[5], Mikhail Spilakov [5], Gael Roue [6], Ken Mills [3], Efterpi Kostareli [1,2]

[1] European University Cyprus, School of Medicine, Frankfurt Campus, Frankfurt, Germany, [2] Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom, [3] Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom, [4] School of Life Sciences, University of Essex, Essex, UK, Functional Gene Control Group, Epigenetics Section, MRC London Institute of Medical Sciences, London, UK, [6] Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute (IJC), 08916 Badalona, Spain



"Oligodendrocyte-Specific Deletion of HIF1α Leads to Dysfunctional Axonal Mitochondria"

Iva D. Tzvetanova[1,2], Sharlen Moore[2], Andrea Trevisiol [2, 3, 4], Marie-Theres Weil [2, 5], Ting Sun [2,6], Torben Ruhwedel [2,5,7], Christos Nardis[2,5], Wiebke Möbius [2,5,7], Livia de Hoz [2,8,9], and Klaus-Armin Nave [2,10]

[1] School of Medicine, European University Cyprus, [2] Department of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany, [3] Physical Sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada, [4] Hurvitz Brain Sciences, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, [5] Electron Microscopy Unit, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany, [6] Center for Molecular Neurobiology Hamburg (ZMNH), Hamburg, Germany, [7] Cluster of Excellence Multiscale Bioimaging: From Molecular Machines to Networks of Excitable Cells (MBExC), University of Göttingen, Göttingen, Germany, [8] Neuroscience Research Center, Charité-Medical University of Berlin, Berlin, Germany, [9] Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK, [10] Department of Neuropathology, Charité-Medical University of Berlin, Berlin, Germany

Chairs: Dr. Charalambos Michaeloudes, PhD Cand. Theodora Christina Kyriakou (1 to 5), Dr. Andreas Yiallouris, Dr. Katerina Menelaou (6 to 11)

Juris



GEORGIADES & ASSOCIATES

Advocates & Legal Consultants

Advocates

SESSION VII

INTERACTIVE WORKSHOP II

SATELLITE SESSION

WELLBEING FUTURES

MENTAL HEALTH & HEALTHY AGEING FOR 2050 AND BEYOND BY NORDIC WELLBEING ACADEMY (NWA) · EUROPEAN HEALTH FUTURES FORUM (EHFF) · CAMBRIDGE MEDICAL ACADEMY

A ONE-DAY FUTURES-ORIENTED ROUNDTABLE WITHIN THE 14TH IMBMC

Chairs: Takis Kotis, CEO Cambridge Medical Academy

Format: Three keynote presentations of 10 minutes each, followed by a 10-minute Q&A with the audience.

This session sets the intellectual and emotional frame for the full day — each speaker offering a distinct disciplinary or institutional lens on the central question: what does it mean to build genuinely healthy, resilient, and connected societies by 2050?

10:10 – 10:55 Total Session time



"The WHO lens on mental health systems in the Eastern Mediterranean, Cyprus's National Mental Health Strategy 2025–2028, and the global healthy ageing agenda"
Dr Irshad Shaikh (tbc)
WHO Europe, Cyprus Country Office



LECTURE IN GREEK LANGUAGE WITH SLIDES IN ENGLISH

"MYRTO, Kapa3's AI-supported Digital Social Navigator"
Evangeli Bista
co-founder and Operations Manager of Kapa3



"Transforming the landscape of mental health - a salutogenic approach"
Mr. Lars Münte
International Director, Nordic Wellbeing Academy; Network Director, European Health Futures Forum. Member, WHO/Europe Public Health Innovation Platform (Domain 4: Public Health Communication & Trust).

Chairs: Prof. Dr. Konstantinos Dimas, Prof. Dr. Anastasis Stephanou

FROM THE NEWS

THE "ELPIDA" FOUNDATION CYPRUS IS AIMING TO UNITE GLOBAL EFFORTS FOR A HEALTHIER FUTURE FOR ALL

10:55 – 11:10



"Can a small country make a global health difference? From national evidence to international action in childhood cancer"
Professor Dr. Loizos Loizou
Clinical Professor of Pediatrics, Pediatric Oncology – Hematology, Medical School, University of Nicosia. Frm. Director of the Pediatric Oncology - Hematology Clinic, Archbishop Makarios III Hospital, Nicosia. President of the ELPIDA Foundation for children and adolescents affected by cancer or leukemia.

SESSION VIIIa

NEW FRONTIERS IN ONCOLOGY
CHRONIC DISEASES AND INTEGRATED MEDICINE
THERAPEUTIC TOOL, NOVELTIES AND EMERGING TARGETS, NATURALPRODUCTS AND REPURPOSING DRUGS
FROM GENETICS TO CLINICAL TRIAL TO CLINICAL PRACTICE: NOVEL AND PIONEER STRATEGIES FOR NEW THERAPEUTIC, SURGICAL AND HOLISTIC APPROACHES

Chairs: Prof. Dr. Konstantinos Dimas, Dr. Anastasis Stephanou

11:10 – 11:25 **Satellite Lecture by EROS-Iasis**



"Patient-Enabled Personalised Cancer Monitoring: Living Nodes in the Internet of BioThings"
Dr. Andreani Odysseos
Director of Biomedical Research EPOS-Iasis, R&D

11:25 – 11:40 **"Endothelin Receptor Blockade Potentiates Adoptive T-Cell and CAR T-Cell Therapies"**



Dr. Philippos Demetriou
The Center for the Study of Haematological and Other Malignancies (CSHM) Nicosia, Cyprus

11:40 – 11:55 **"Zebrafish Avatars: A Translational Model for Cancer Pharmacology & Precision Oncology"**



Assist. Prof. Dr. Nikolas Dietis
University of Cyprus Medical School and the Head of the Experimental Pharmacology Laboratory at UCY, University of Cyprus

SURGICAL AND OTHER NOVEL MOLECULAR APPROACHES FOR DIFFERENT DIFFICULT DYSPLASIA, HAEMATOLOGICAL AND ONCOLOGICAL CASES. ENCOUNTER WITH THE PIONEERS

Chairs: Assoc. Prof. Dr. Athanasios Petrou, Assist. Prof. Dr. Periklis Zavrides

11:55 – 12:10 **"Which are the boundaries in using Robotic System DaVinci on a challenging oncological case"**



Clin. Assoc. Prof. Dr. Dimitrios Kyparissopoulos
IASO Medical center; Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust, London, UK; Head of Thoracic Department, IASO Hospital, Athens, Greece, and Adj. Ass. Prof. in Robotic Surgery, European University Cyprus.

12:10 – 12:25 **"Modern Bone Marrow Transplantation: Breakthroughs Improving Survival and Quality of Life"**



Clin. Prof. Dr. Manolis Nikolousis
Consultant Hematologist and Bone Marrow Transplantation
Program Director for Acute Leukemia and stem cell transplantation at Yas Clinic. Abu Dhabi

12:25 – 12:40 **"HoLEP (Holmium Laser Enucleation of the Prostate) for benign prostatic hyperplasia"**



Clin. Assoc. Prof. Dr Marios Hadjipavlou
Consultant Urological Surgeon, El Greco Medical Centre, Nicosia, The Princess Grace Hospital, London, UNIC School of Medicine, King's College London School of Medicine

SESSION VIIIb

LATEST NEWS IN ONCOLOGY. IS THERE ANY LIGHT AT THE END OF THE TUNNEL?

Chairs: Prof. Dr. Pavlos Kosteas, Haris Charalambous, Elena Andreou

12:40 – 13:00 **KEYNOTE SPEAKER**



Professor Dr. George Vasiliou (HYBRID)
Professor of Haematological Medicine, Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Leukemic hemopoietic stem cells, University of Cambridge, UK

"Understanding clonal haematopoiesis for myeloid cancer prevention"

13:00 – 13:15 **"P90 ribosomal S6 kinases: A bona fide target for novel targeted anticancer therapies?"**



Professor Dr. Konstantinos Dimas
Department of Pharmacology
Medical School of the University of Thessaly, Greece

13:15 – 13:30 **"Modern Approaches to Non-Melanoma Skin Cancer: Traditional and New Advances in Basal (BCC) and Squamous Cell Carcinoma (SCC) Treatment"**



Assoc. Prof. Dr. Efterpi Zafeiriou
Assoc. Prof. of dermatology, Head of Dermatology Department, University of Thessaly, University Hospital of Larisa, Greece

13:30 – 13:50 **KEYNOTE SPEAKER**



Professor. Dr. Vasso Apostolopoulos
Distinguished Professor, School of Health and Biomedical Sciences, RMIT University, Melbourne VIC Australia, Expertise in development of drugs and vaccines

"From Bench to Bedside: Translating Cancer Vaccine Research into the Clinic"

13:50 – 14:10 **KEYNOTE SPEAKER**



ProfessorDr. Evanthia Galanis (HYBRID)
Professor of Oncology and Executive Dean of Development, Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, USA

"Next-Generation Cancer Immunotherapy: from Mechanism to Medicine"

14:10 – 14:50 **Lunch Buffet**
POSTER SESSION

SESSION IX

SATELLITE BY PAIN CLINIC, NICOSIA CYPRUS

INTERACTIVE WORKSHOP II

CANCER PAIN

SESSION COORDINATOR: ASSIST. PROFESSOR DR. PERIKLIS ZAVRIDES, SCHOOL OF MEDICINE, EUC

Chairs: Prof. Dr. Marios Pantzaris, Dr. Alexis Papadopoulos, Dr. Dimitrios Vomvas

Format: 10-minute "flash" presentations followed by 20-minute moderated debate (interactive discussion)

14:50 – 15:00 **"Interventional Cancer Pain Management: Beyond Opioids, Beyond Boundaries"**



Assistant Prof. Dr. Periklis Zavrides
Anesthesiologist, Algologist, School of Medicine, European University Cyprus, Cyprus Pain Clinic

15:00 – 15:10 **"A Practical Approach to Pharmacological Management of Cancer Pain"**



Dr. Marouli Diamantina
Anesthesiologist, Intensivist, German Oncology Center, Limassol, Cyprus

15:10 – 15:20 **"Optimal cancer pain management: let's collaborate. A medical oncologist's perspective"**



Dr. Pantelis Kountourakis
Director of the Oncology Department, Mediterranean Hospital, Limassol, Cyprus

15:20 – 15:40 **20-minute moderated debate (interactive discussion)**

Pfizer

SESSION Xa

SENDOCRINOLOGY, DIABETES, INTERNAL MEDICINE: THE MAGNITUDE OF AN UNRESOLVED PROBLEM, ADVANCES AND NEW TREATMENT APPROACHES

Chairs: Dr. Giorgos Moustras, Dr. Argyrios Tsakalis, Dr. Ioannis kyriazis **(HYBRID)**

15:40 – 15:55 **"GLP-1, SGLT2, and Beyond: Redefining Diabetes Care in Internal Medicine"**



Dr. Nadia Othonos
specialist in Endocrinology and Diabetes, The Care Medical Institute.

15:55 – 16:10 **"Clinical and pathophysiological relevance of thyroid dysfunction to the development and progression of MASLD: The role of Resmetirom"**



Professor Dr. Erifili Hatziagelaki
Professor Erifili Hatziagelaki, MD, PhD; Professor of Internal Medicine and Metabolic Diseases, School of Medicine, National and Kapodistrian University of Athens, Greece
Clinical Professor of Internal Medicine and Metabolic Diseases, European, University Cyprus, Nicosia, Cyprus
Visiting Professor, German Diabetes Center (DDZ), Heinrich Heine, University Düsseldorf, Germany

16:10 – 16:25 **"The Future of Endocrinology: Obesity, Diabetes and the Quest for Healthy Longevity"**



Assoc. Prof. Dr. Polys Evripidou (HYBRID)
Consultant Diabetologist, Limassol, Cyprus; School of Medicine University of Cyprus, Nicosia, Cyprus

16:25 – 16:40 **"D-dimer assay: over-testing in Venous thromboembolism (VTE)?"**



Professor Dr. Christos Savvopoulos (HYBRID)
Prof. of Internal Medicine, Aristotle University of Thessaloniki, Director of 1st Medical Propedeutic Dept of Internal Medicine & Stroke Unit, Excellence Center of Hypertension, AHEPA University Hospital

Ophthalmos
Research & Educational Institute

SESSION Xb

Chairs: Dr. Panayiotis Economides, Dr. Doros Loizou, Dr. Michalis Hinis

16:40 – 17:00 **KEYNOTE SPEAKER**



Professor Dr. Arne Astrup (HYBRID)
Obesity Specialist, University of Copenhagen

"From discovery of GLP-1 as a satiety hormone to GLP-1-based medications in the clinical management of cardiometabolic diseases and cancer"

17:00 – 17:15 **"Anti-Obesity Medications: Current Options and Future Developments"**



Assoc. Prof. Dr. Stavroula A. Paschou
Assoc. Professor of Endocrinology, Head of Endocrine Unit and Diabetes Center, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

17:15 – 17:35 **KEYNOTE SPEAKER**



Professor Dr. Peter Rossing
Head of Clinical Translational Research, Steno Diabetes Center Copenhagen (SDCC) Herlev, Professor of Endocrinology, University of Copenhagen, Denmark

"Bridging Kidney and Cardiac Health from Type 2 Diabetes to Type 1 Diabetes: Semaglutide as the New Pillar of Diabetic Kidney Disease Treatment"

Announced By: Prof. Dr. Ioannis Patrikios

17:35 – 18:15 **HONORARY KEYNOTE SPEAKER**



Prof. Dr. Drs. h.c. Emmanuelle Charpentier, ForMemRS
Nobel Laureate 2020
Max Planck Unit for the Science of Pathogens, Nobel in Chemistry 2020

"The bacterium as inventor: microbial biology as an innovation pipeline"

18:05 – 18:30 **Coffee and refreshments**

PAPAELLINAS GROUP

ΥΓΕΙΑ | ΟΜΟΡΦΙΑ | ΕΥΕΞΙΑ

ΠΑΠΑΕΛΛΗΝΑΣ
ΟΜΙΛΟΣ

Αποστολή μας, να κάνουμε
όλο και περισσότερους ανθρώπους
να ζουν και να νιώθουν
καλύτερα.



www.papaellinasgroup.com.cy

14th International Multithematic Scientific Bio-Medical Congress (IMBMC)

"Bio-medical Scientific Cyprus"

SATURDAY, 21 NOVEMBER 2026

Program

08:00 – 08:30 **Registration**



Cardiology sessions In Memoriam: of the cardiology legend Professor Dr. Eugene Braunwald who passed away on April 22, 2026.

10:30
Room: OMEGA

GO TO APENDIX I FOR THE HANDS-ON HIGHLY SPECIALIZED WORKSHOP

ADVANCED ECHOCARDIOGRAPHIC TECHNIQUES

Coordinator: Clin. Prof. Dr. Constantinos Papadopoulos

SESSION XI
SATELLITE BY ΚΟΑ

THE SESSION WILL BE OFFERED IN GREEK LANGUAGE

PRE-ATHLETICS MEDICAL & CARDIOLOGICAL CHECKUP

Χορηγούνται 3 μονάδες Συνεχιζόμενης Ιατρικής Εκπαίδευσης από την Επιτροπή ΣΙΕ/ΣΕΑ του ΠΙΣ

ΚΥΠΡΙΑΚΟΣ ΟΡΓΑΝΙΣΜΟΣ ΑΘΛΗΤΙΣΜΟΥ
ΑΝΩΤΑΤΟ ΣΥΜΒΟΥΛΙΟ ΥΓΕΙΑΣ ΑΘΛΗΤΩΝ
ΠΑΓΚΥΠΡΙΟΣ ΙΑΤΡΙΚΟΣ ΣΥΛΛΟΓΟΣ

5^{0} ΕΚΠΑΙΔΕΥΤΙΚΟ ΣΕΜΙΝΑΡΙΟ ΓΙΑ ΤΟΝ ΠΡΟΑΘΛΗΤΙΚΟ ΙΑΤΡΙΚΟ & ΚΑΡΔΙΟΛΟΓΙΚΟ ΕΛΕΓΧΟ ΓΙΑ ΤΗΝ ΕΚΔΟΣΗ ΤΟΥ ΔΕΛΤΙΟΥ ΥΓΕΙΑΣ

ΣΑΒΒΑΤΟ 21 ΝΟΕΜΒΡΙΟΥ 2026, 09:00-12:40

Τόπος εκδήλωσης: Αμφιθέατρο, Ευρωπαϊκό Πανεπιστήμιο Κύπρου, Λευκωσία
Γλώσσα Σεμιναρίου: Ελληνική

Υψηλή Εποπτεία: Κυπριακός Οργανισμός Αθλητισμού (ΚΟΑ), Ανώτατο Συμβούλιο Υγείας Αθλητών (ΑΣΥΑ), Παγκύπριος Ιατρικός Σύλλογος (ΠΙΣ)

Επιστημονική Οργάνωση: Επιστημονική Επιτροπή ΑΣΥΑ & Επιστημονική Επιτροπή ΠΙΣ
- Δρ. Πέτρος Αγαθαγγέλου, Πρόεδρος Επιστημονικής Επιτροπής ΑΣΥΑ & Πρόεδρος ΠΙΣ
- Δρ. Λοΐζος Αντωνιάδης, Μέλος Επιστημονικής Επιτροπής ΑΣΥΑ, Πρόεδρος Κυπριακού Ινστιτούτου Καρδιολογίας Έρευνας και Μελέτης Κληρονομικών Καρδιαγγειακών Νοσημάτων (ΚΙΚΕΜΜ)

ΠΡΟΓΡΑΜΜΑ

08:30 – 09:00 **Προσέλευση - Εγγραφές (συστήνεται να γίνεται ηλεκτρονική προεγγραφή στην ηλεκτρονική διεύθυνση: mesiti.n@sportskoa.org.cy**

09:00 – 11:00 **ΠΡΩΤΗ ΕΝΟΤΗΤΑ**



Προεδρείο:
Δρ. Ήρα Μούστρα Ηρακλέους, πρώην Πρόεδρος Καρδιολογικής Εταιρείας Κύπρου
Δρ. Ελευθέριος Νικολαΐδης, Καρδιολόγος
Δρ. Φοίβος Χριστοφίδης, Παθολόγος

09:00 – 09:20 **Προσφωνήσεις**



Δρ. Πέτρος Αγαθαγγέλου,
Πρόεδρος Ανώτατου Συμβουλίου Υγείας Αθλητών (ΑΣΥΑ)



Ιωάννης Ιωάννου,
Πρόεδρος Κυπριακού Οργανισμού Αθλητισμού (ΚΟΑ)

09:20 – 09:45 **(15 λεπτά παρουσίαση,10 λεπτά σχόλια & ερωτήσεις)**



Δελτίο Υγείας, Πληροφορίες που λαμβάνονται από το Ατομικό, το Κληρονομικό Ιστορικό και την Κλινική εξέταση. Πρακτικά παραδείγματα από την αξιολόγηση των ΔΥ του ΚΟΑ.

Εισηγητής: Δρ. Λοίζος Αντωνιάδης MD PhD, Αν. καθηγητής Καρδιολογίας Ευρωπαϊκού Πανεπιστημίου Κύπρου.

Σχολιαστές: Δρ. Λευτέρης Καλλέργης Επεμβατικός Καρδιολόγος Πανεπιστημιακό Νοσοκομείο Κρήτης, Δρ. Σωτήρης Αντύπας Καρδιολόγος, Δρ.Κωνσταντίνος Μακρίδης Καρδιολόγος, Δρ. Πρόδρομος Μιχαήλ Καρδιολόγος, Δρ. Τατιάνα Μιχαηλίδου Καρδιολόγος, Δρ. Ιωάννης Στεφάνου Καρδιολόγος, Δρ.Παναγιωτίδης Ιωάννης Καρδιολόγος

09:45 – 10:10 **(15 λεπτά παρουσίαση,10 λεπτά σχόλια & ερωτήσεις)**



Ποια είναι τα Κληρονομικά Καρδιαγγειακά Νοσήματα και πώς σχετίζονται με τον Αιφνίδιο Θάνατο των Νέων και Αθλητών.

Εισηγητής: Δρ. Άρης Αναστασάκης MD PhD, Consultant Cardiologist, Scientific Director Unit of Inherited and Rare Cardiovascular Diseases. Onasis Cardiac Surgery Center, Athens.

Σχολιαστές: Δρ. Μάριος Ιωαννίδης Καρδιολόγος ΓΝΛευκωσίας, Δρ. Βιολέττα Αναστασιάδου Ιατρός Γενετικής, Καραισκάκιο Ίδρυμα, Δρ.Μαρία Καρακύριου Καρδιολόγος π. Γ.Γ.ΚΕΚ, Δρ.Ηλίας Παπασσάβας Καρδιολόγος Αρρυθμιολόγος, Δρ.Βίκη Ζένιου Καρδιολόγος, Δρ.Σαββίδης Κώστας Καρδιολόγος, Δρ.Πούλλος Μιχαήλ Καρδιολόγος.

10:10 – 10:35 **(15 λεπτά παρουσίαση,10 λεπτά σχόλια & ερωτήσεις)**



Αξιολόγηση του ΔΥ από την σκοπιά του Παθολόγου και του Ιατρού Γενικής Ιατρικής Παρουσίαση περιστατικών από το αρχείο του ΚΟΑ.

Εισηγητής: Δρ Γεώργιος Μιλτιάδους, Ειδικός Παθολόγος, Πρόεδρος Ιατρικού Συλλόγου Λευκωσίας Ιπποκράτης

Σχολιαστές: Δρ. Σπύρος Παπαιωάννου Δ/ντής Καρδιολογίας Ναυτικό Νοσοκομείο Αθηνών, Δρ. Κώστας Σχίζας Παθολόγος, Δρ. Κυριάκος Παναγή Παθολόγος, Δρ. Ανδρέας Ιωάννου Παθολόγος, Δρ. Ευρυπίδης Λοιζίδης Καρδιολόγος, Δρ. Αριάδνη Στυλιανού Καρδιολόγος, Δρ. Νίκος Μαρκαντώνης Καρδιολόγος, Δρ. Μάριος Λεμονιάτης Καρδιολόγος, Δρ. Παντελής Γεωργίου Καρδιολόγος, Δρ. Ανδρέας Καλλής Παθολόγος

10:35 – 11:00 **Διάλειμμα**

11:00 – 12:15 **ΔΕΥΤΕΡΗ ΕΝΟΤΗΤΑ**





Προεδρείο:

Δρ. Γεωργία Δανιήλ, Καρδιολόγος, Πρόεδρος Ο.Ε. Καρδιολογικής Εταιρείας Κύπρου

Δρ. Αργύρης Κυθρεώτης, Καρδιολόγος-Παιδοκαρδιολόγος

Δρ. Πατρίκιος Ιωάννης, Καθηγητής Ιατρικής Σχολής Ευρωπαϊκού Πανεπιστημίου Κύπρου

11:00 – 11:35 **(25 λεπτά παρουσίαση,10 λεπτά σχόλια & ερωτήσεις)**



Αξιολόγηση του ΗΚΓ στα μικρά παιδιά και εφήβους. Παρουσίαση περιστατικών.

Εισηγητής: Δρ. Μαργαρίτα Μπαρτζώκα, Παιδοκαρδιολόγος

Σχολιαστές: Δρ. Ανδρέας Ρουσουνίδης Παιδοκαρδιολόγος, Δρ. Παναγιώτης Ζαβρός Παιδοκαρδιολόγος, Δρ. Αντώνιος Ιωσήφ Παιδοκαρδιολόγος, Δρ. Μαρία Παπαφυλακτού Παιδοκαρδιολόγος, Δρ. Στέλιος Καρβουνάρης Καρδιολόγος, Δρ. Χριστόδουλος Κοντός Καρδιολόγος, Δρ. Χατζησάββα Ουρανία Καρδιολόγος

NOVARTIS

11:35 – 12:10 (25 λεπτά παρουσίαση,10 λεπτά σχόλια & ερωτήσεις)

Ηλεκτροκαρδιογραφικός (ΗΚΓ) έλεγχος στους αθλητές. Ποια ΗΚΓραφικά ευρήματα είναι φυσιολογικά και ποια χρήζουν περαιτέρω αξιολόγησης. Παγίδες στην αξιολόγηση του ΗΚΓ. Παρουσίαση περιστατικών

Εισηγητής: Δρ. Άρης Αναστασάκης MD PhD, Consultant Cardiologist, Scientific Director Unit of Inherited and Rare Cardiovascular Diseases. Onasis Cardiac Surgery Center, Athens.

Σχολιαστές: Δρ. Γεώργιος Ανδρικόπουλος Δ/ντής Καρδιολογίας Νοσοκομείο Ερρίκος Ντυνάν Αθήνα, Δρ. Ευαγόρας Νικολαίδης Καρδιολόγος, Δρ. Μάρκος Αγαθαγγέλου Καρδιολόγος, Δρ. Παντελής Κουρτελλάρης, Ηλεκτροφυσιολόγος, Δρ. Νίκος Καρπέττας Καρδιολόγος, Δρ. Ιωσήφ Μουτήρης Καρδιολόγος π. Δ/ντής Γ.Ν.Πάφου. Δρ. Ανδρέας Ανδρέου Επεμβατικός Καρδιολόγος, Δρ. Αντρέας Τρύφωνος π. Δ/ντής Καρδιολογίας Γ.Ν.Λεμεσού.


Δρ. Γεώργιος Ανδρικόπουλος


Δρ. Σπύρος Παπαιωάννου


Δρ. Λευτέρης Καλλέργης

12:15 **ΤΕΛΟΣ ΣΕΜΙΝΑΡΙΟΥ**
Τα Πιστοποιητικά Παρακολούθησης και οι Μονάδες Συνεχιζόμενης Ιατρικής Εκπαίδευσης από την Επιτροπή ΣΙΕ/ΣΕΑ του ΠΙΣ θα αποσταλούν ηλεκτρονικά στους συμμετέχοντες .

12:15 – 12:45 **Lunch Buffet**
POSTER SESSION

Οδοντοτεχνικό Εργαστήριο
Ψηφιακής Τεχνολογίας
ΘΕΟΔΟΣΙΟΣ ΧΑΤΖΗΤΤΟΦΗΣ
Σταδίου 51, Στρόβολος, ΤΚ 2058, Λευκωσία - Κύπρος
Τηλ. +357 22 316568 - Κιν. 99316101
Skype: xteodentCyprus
e-mail: xteodentcy@gmail.com

SESSION XII:
INTERRACTIVE WORKSHOP IV
"AMYLOIDOSIS: THE MULTIDISCIPLINARY FRONT"

Coordinated by: Vis. Prof. Dr. Filippos Triposkiadis and Clin. Prof. Dr. Petros Agathaggelou, Georgios M. Georgiou

Chairs: Prof. Dr. Panagiotis Avraamides, Prof. Dr. Filippos Triposkiadis, Clin. Assist. Prof. Dr. Constantinos Economides

Format: 10-minute "flash" presentations followed by 2 x 15-minute moderated debate on a difficult case study

12:45 – 12:55 **"Amyloidosis Without Borders: Lessons for Haematologists, Cardiologists and Beyond"**



Clin. Prof. Dr. Manolis Nikolousis
Consultant Hematologist and Bone Marrow Transplantation, Program Director for Acute Leukemia and stem cell transplantation at , Yas Clinic. Abu Dhabi

12:55 – 13:05 **"Guiding Treatment Decisions in Cardiac Amyloidosis: Evidence-Based Approaches and Emerging Therapies"**



Clin. Assoc. Prof. Dr Andreas Synetos
School of Medicine, European University Cyprus, Interventional Cardiologist at Hippokrateion Hospital and Consultant at the First Department of Cardiology at the Medical School of Athens, Greece

13:05 – 13:20 **"Role of Invasive Cardiology in Cardiac Amyloidosis: Novel Techniques, Device Therapy, and Procedural Considerations. When and How to Intervene?"**



Professor Dr. Konstantinos Toutouzas
National and Kapodistrian University of Athens, Head of the Department of Structural Cardiopathies and Cardio-oncology, First University Cardiology Clinic, Hippocrates Hospital

HOSPITAL CASE PRESENTATIONS

Commendatores: Clin. Prof. Dr. Evagoras Economides, Dr. Theodoros Christodoulides and all session speakers

Format: 10-minute "flash" presentations followed by 2 x 15-minute moderated debate on a difficult case studies

13:20 – 14:00 **CASES FOR PRESENTATION AND DISCUSSION**



CASE STUDY IN LARISSA' S UNIVERSITY HOSPITAL
"Difficult Case Presentation by Larissa' s University Hospital"
Assist. Prof. Dr. Andreas Xanthopoulos
University General Hospital of Larissa, Larissa, Greece



CASE STUDY IN NICOSIA'S GENERAL HOSPITAL
"Case Presentation by Nicosia s' General Hospital: delayed diagnosis for otherwise not that difficult incident"
Dr. Marios Ioannides
Consultant Cardiologist and Assistant Director of the Cardiology Department, Nicosia General Hospital, Cyprus

SESSION XIII:
"PRECISION MEDICINE IN CARDIOMYOPATHY"

Coordinated by: Prof. Dr. Filippos Triposkiadis

ENCOUNTER WITH THE PIONEERS METHODS & CASE STUDIES

Chairs: Dr. Nicos Eteokleous, Clin. Ass. Prof. Dr. Hera Heracleous, Clin. Prof. Dr Petros Agathaggelou

A LAST MIN INSERT: A NOTE FOR PREVENTION

14:00 – 14:15 **"Lipid Management After Stroke: From LDL-C Lowering to Emerging Cardiometabolic Risk Factors"**



Professor Dr. Haralampos Milionis
Professor of Internal Medicine, Head of the 1st Division of Internal Medicine; Department of Internal Medicine; Faculty of Medicine, School of Health Sciences, University of Ioannina

"PRECISION MEDICINE IN CARDIOMYOPATHY"

14:15 – 14:30 **"Targeting the Sarcomere: Do Myosin Inhibitors End the Need for Septal Myectomy"**



Clin. Assoc. Prof. Dr Andreas Synetos
School of Medicine, European University Cyprus, Interventional Cardiologist at Hippokrateion Hospital and Consultant at the First Department of Cardiology at the Medical School of Athens, Greece

14:30 – 14:45 **"Digital Twins and AI Mapping: The Future of Non-Invasive Tissue Biopsy"**



Dr. Aikaterini Christidi (HYBRID)
EACVI Level 3 Certified in Cardiovascular Magnetic Resonance (CMR); Head of the Cardiovascular Magnetic Resonance Department General Clinic of Thessaloniki, Greece

14:45 – 15:00 **KEYNOTE SPEAKER**



Professor Dr. Antonio Pelliccia (HYBRID)
Expert in Sports Medicine, School of Sport Medicine. University of Rome and L'Aquila
"Exercise and Sport in patients with hypertrophic cardiomyopathy "

15:00 – 15:15 **"The Status of Gene Therapy in Hereditary Cardio-myopathies: The Clinician's View"**



Professor Dr. Filippos Triposkiadis
Ex. Director of the Dept. of Cardiology of the Larissa University Hospital; School of Medicine, Larissa, Greece, Visit. Prof. School of Medicine and MSc on Heart Failure and Cardiomyopathies Coordinator, European University Cyprus, Cyprus

15:15 – 15:30 **"Artificial intelligence and digital technology in cardiovascular imaging"**



Clin. Prof. Dr. Constantinos Papadopoulos
Director of the 2nd Cardiology Clinic, Korgialenio-Benakio Hospital, Head of the Echocardiography Laboratory and the Heart Failure Clinic, Co-Chair of the European Committee for Transesophageal Echocardiography Examinations
"Korgialenio-Benakio, Hellenic Red Cross" General Hospital of Athens, Athens, Greece

SESSION XIV:
HEART FAILURE
CARDIOLOGY TODAY AND WHERE THE FUTURE TAKES US
FOCUS ON TODAY TO ENLIGHTEN THE FUTURE
"PERSONALISING CARDIOVASCULAR CARE"
ENCOURAGING PATIENTS THROUGH TAILORED TREATMENTS TO IMPROVE OUTCOMES, REDUCE RISK, AND REDEFINE THE STANDARD OF CARE

Chairs: Dr. Stelios Hadjistyllis, Dr. Costakis Aroditis, Prof. Dr. Konstantinos Makaritsis

15:40 – 15:50 **"Expansion of ARNI and MRA Therapy across the LVEF Spectrum"**



Professor Dr. Katerina Naka
Professor of Cardiology at Faculty of Medicine, School of Health Sciences, University of Ioannina, **2nd Department of Cardiology, University Hospital of Ioannina, Greece**

15:50 – 16:00 **"From Weight Loss to Cardioprotection: Tirzepatide's Role in the HF Treatment"**



Visit. Assoc. Prof. Dr. Elias Tsougkos
Associate Professor of Cardiology, European University Cyprus
Director, 6th Cardiology Department, Hygeia Hospital, Athens, Greece, Head Cardiologist, Hellenic Olympic Committee

16:00 – 16:10 **"Hypertension with comorbidities: the usual suspect for heart failure with preserved ejection fraction"**



Adj. Prof. Dr. Andreas Pittaras
Clinical Hypertension Specialist ESH, George Washington University, Washington DC, USA
Adjunct Professor, School of Medicine, European University Cyprus

16:10 – 16:20 **"Revascularization in isshaemic cardiomyopathy: where do we stand?"**



Professor Dr. Lambros Michalis
Professor of Cardiology in the School of Medicine, University of Ioannina, Greece; Director of University Hospital of Ioannina 2nd Department of Cardiology; President of the UEMS Cardiology Section. **President of Hellenic Society of Cardiology.**

16:20 – 16:30 **"Controversies in Heart Failure"**



Professor Dr. Gerasimos Filippatos
Professor and Chairman of the Department of Cardiology and Director of the Heart Failure and Cardioncology Unit at the Attikon University Hospital, Athens, Greece.

HOSPITAL CASE PRESENTATIONS

Commendatores: Clin. Prof. Dr. Evagoras Economides, Dr. Theodoros Christodoulides and all session speakers

Format: 10-minute "flash" presentations followed by 2 x 10-minute moderated debate on a difficult case studies

16:30 – 17:00 **Nicosia General Hospital:** Presentation of a difficult case



Dr. Kimon Myrianthopoulos
Cardiology Clinic, Nicosia General Hospital

"Old Myocardial Infarction" to Arrhythmogenic Cardiomyopathy: Unravelling the Cause of Syncope, Ventricular Tachycardia and Heart Failure



Pafos Hospital: Presentation of a difficult case

Dr. Angeliki Mouzarou
Consultant Cardiologist
Head of Cardiology Dept., Paphos GH, State Health Services Organization Cyprus

"Four Coronary Events Despite Intensive LDL Cholesterol Lowering: The Double Hit of Familial Hypercholesterolaemia and Elevated Lipoprotein(a)"

HIGHLIGHTS
KEYNOTE LECTURES BY THE SPECIALISTS

Chairs: Clin. Prof. Dr. Petros Agathaggelou, Prof. Dr. Konstantinos Toutouzas, Adj. Prof. Dr. Charalambos Grassos

17:00 – 17:15 **KEYNOTE SPEAKER**



Professor Dr. Randall C. Starling
Professor of Medicine; Cleveland Clinic Lerner College of Medicine of the Case Western Reserve University, Kaufman Center for Heart Failure Treatment and Recovery, Cleveland Clinic Foundation, Cleveland, Ohio USA

"Guideline Directed Medical Therapy in Patients with severe, advanced heart failure"

17:15 – 17:35 **KEYNOTE SPEAKER**



Professor Dr. John Floras
Professor of Medicine, University Health Network and Sinai Health Division of Cardiology, University of Toronto, Canada

"Sleep-disordered breathing in heart failure"

17:35 – 17:55 **KEYNOTE SPEAKER**



Professor Dr. CeciliaLinde
President Elect the European Society of Cardiology 2024-2026 Executive Editor for European Heart Journal Professor of Cardiology at Karolinska Institutet, Senior Consultant at Heart, Vascular and Neurology Theme, Karolinska University Hospital

"From CRT to Conduction System Pacing: Redefining Cardiac Resynchronization in the Era of Precision Heart Failure Care"

SESSION XV: ARRHYTHMIAS

MEETING WITH THE EXPERTS

WAYS OF TREATMENT FOR PROPER THERAPY: IS THERE SUCH A THING?
CASES DISCUSSION

Chairs: Dr. Eleftherios Nicolaides, Dr. Ilias Papassavas

Format: a 4 x 15-minute moderate debate on difficult cases study.
(7 min presentation each followed by 8 min debate)

17:55 – 18:10 **"Difficult case study"**



15-minute moderated debate

Professor Dr. Vasilis Vasilikos
Aristotle University of Thessaloniki, Director of 3rd Cardiology Clinic Cardiology Department
Hippokrateion General Hospital, Thessaloniki

18:10 – 18:25 **"Difficult case study"**



15-minute moderated debate

Dr. Pantelis Kourtellaris
Cardiologist-Electrophysiologist Consultant
American Medical Center- American Heart Institute, Nicosia, Cyprus

18:25 – 18:40 **"Difficult case study"**



15-minute moderated debate

Dr. George K. Andrikopoulos
President of the Hellenic Arrhythmia Institute, Director of Cardiology and the Department of Electrophysiology and Pacing, Henry Dunant Hospital

18:40 – 18:55 **"Diagnostic Electrophysiology study: how far should we go"**



5-minute moderated debate

Professor Dr. Charalampos Kriatseli
Head of Electrophysiology, Vivantes Klinikum Neukölln, Berlin, Germany and Areteion Hospital, Nicosia, Cyprus

Commendatores: Clin. Prof. Dr. Petros Agathaggelou, Prof. Dr. Elias Koutsiogiorgis (NU)

18:55 – 19:00 **POSTER AWARDS**

Congress Poster Award Committee:

Prof. Dr. Costantinos Dimas
School of Medicine, University of Crete

Prof. Dr. Kyriakos Kypreos
School of medicine, University of Patra

Prof. Dr. Ioannis Patrikios Closing Remarks



LEQVIO®
inclisiran

Transform LDL-C management

Choose LEQVIO® for early, strong and sustained LDL-C reduction*[1-5]

LEQVIO® uniquely lowers LDL-C† with two injections a year (after 2 initial doses),‡ helping your eligible patients reach their LDL-C goal early and maintain it over the long-term.§[1-5]

* In clinical trials, LEQVIO® allowed most patients to achieve their LDL-C goals by Day 30 (80.8% vs 11.3% with SOC; N=1,770)[1] and provided 52.3% LDL-C reduction at Month 17 (mean difference vs placebo from baseline [N=1,561; 95% CI: -56, -49; p<0.0001]) on top of statins[1,3] in line with the ESC 2025 guidelines (minimum 50% reduction after an event).[4] LDL-C reduction was maintained during each 6-month dosing interval.[1,3]

† From baseline.

‡ LEQVIO® is administered as single subcutaneous injections at the start of treatment, again at 3 months and every 6 months thereafter.[1]

§ The main adverse events observed with LEQVIO® in clinical trials were mostly mild injection-site reactions (8.2% with LEQVIO® vs 1.8% with placebo).[1]

Leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and nonfamilial) or mixed dyslipidaemia, as an adjunct to diet, and in paediatric patients aged 12 years and older with heterozygous familial hypercholesterolaemia (HeFH):
- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin,
- or alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.[1]

CI, confidence interval; **ESC,** European Society of Cardiology; **LDL-C,** low-density lipoprotein cholesterol; **SOC,** standard of care

References: 1. Leqvio® Summary of Product Characteristics- 03.08.2026. **2.** Wright RS, Raal FJ, Koenig W, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. *Cardiovasc Res.* 2024;120(12):1400-1410. doi:10.1093/cvr/cvae109. **3.** Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. *N Engl J Med.* 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387. **4.** Landmesser U, Laufs U, Schatz U, et al. Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. *Eur Heart J.* 2025;doi:10.1093/eurheartj/ehaf685. **5.** Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. *N Engl J Med.* 2017;376(15):1430-1440. doi: 10.1056/NEJMoa1615758. **6.** Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J.* 2025. doi:10.1093/eurheartj/ehaf190.

Pack and price: LEQVIO solution for injection 284mg/1.5ml in pre-filled syringe (with needle guard): €2394,08.

Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to: Novartis Pharma Services Inc., Methonis Tower, 73 Makarios Avenue, 1070 Nicosia, Tel: +357 22 690 690 (Pharmacovigilance Department), Fax: +357 22 315032 or to Pharmaceutical Services, Ministry of Health, CY-1475, www.moh.gov.cy/phs, Tel: +357 22 608 632/661, Fax: +357 22 608 649, by completing the Yellow Card which is available to the public pharmacies or electronically in the website www.kitrinikarta.gov.cy.

NOVARTIS

Novartis Pharma Services Inc.
Methonis Tower, 73 Makarios Avenue, 1070 Nicosia, Tel: +357 22 690 690, Fax: +357 22 496 798

SCAN HERE FOR LEQVIO® PRESCRIBING INFORMATION

LEQ-AD-09.26-CY

14th International Multithematic Scientific Bio-Medical Congress (IMBMC)

"Bio-medical Scientific Cyprus"

WORKSHOPS

THE STAR WORKSHOP*

EVERY DAY BETWEEN 10:00 TO 13:00

MEET THE GREATEST MINDS IN THE WORLD

All delegates can have the ability and access to meet with the invited scientists for face-to-face discussion and possible networking.

Limited Seats: Participation only by Pre- Registering

ENERGON



Delorbis Pharmaceuticals Ltd
17, Athinon Street, Ergates Industrial Area, 2643 Ergates, Lefkosia, Cyprus. P.O. Box: 28629, 2081 Lefkosia, Cyprus.
T. +357 22 845 000, www.delorbispharma.eu

Stay connected with us on social

APENDIX I

SPONSORED BY PHATISCO / GENERAL ELECTRIC

SATURDAY NOVEMBER 21ST

10:30 – 13:30

HANDS-ON WORKSHOP I

HIGHLY SPECIALIZED

ADVANCED ECHOCARDIOGRAPHIC TECHNIQUES

THREE HOURS "HANDS ON – HOW TO DO" COURSE ON WORKSTATIONS



Coordinating Trainer:
Dr. Constantinos H. Papadopoulos

Director of the 2nd Cardiology Clinic, Korgialenio-Benakio Hospital, Head of the Echocardiography Laboratory and the Heart Failure Clinic, Co-Chair of the European Committee for Transesophageal Echocardiography Examinations

Myocardial deformation – Speckle Tracking Imaging

12:00 - 12:45 Myocardial Strain and Work of the Left ventricle
12:45 - 13:30 Myocardial Strain of the Right ventricle and Left atrium

Three-dimensional echocardiography

13:30 - 14:15 3D IMAGING OF CARDIAC CHAMBERS (LV, RV, LA)
14:15 - 15:00 3D Imaging of cardiac valves (MV and TV)

PROTON MEDICAL

PARALLEL MEETING SESSIONS

PARALLEL WORKSHOP II

(Auditorium: Beta)

WELLBEING FUTURES

MENTAL HEALTH & HEALTHY AGEING FOR 2050 AND BEYOND

A one-day futures-oriented roundtable within the 14th IMBMC

20 November 2026 · European University Cyprus · Nicosia, Cyprus

Dates: Thursday 19 November and Friday 20 November 2026
Host venue: European University Cyprus (EUC), Nicosia, Cyprus
Parent events: 14th International Multithematic Bio-Medical Congress (IMBMC) — 19–21 November 2026
Title: Wellbeing Futures: Mental Health & Healthy Ageing for 2050 and Beyond
Organisers: Nordic Wellbeing Academy (NWA) · European Health Futures Forum (EHFF) · Cambridge Medical Academy

NOVEMBER 19

ESession 0

School of Medicine, Lecture Room

(60 min) **Welcome to Cyprus**
Global Mental Health Perspectives

Speakers from the global OHOR community presents

Facilitated by: Lars Münter, Takis Kotis

NOVEMBER 20

09:30 – 10:15 **Session 1**

(Caltura Center Auditorium) **Main Track Keynote Session**

PHADISCO
Quality Healthcare

10:30 – 11:45 (Auditorium B) (75 min)

Session 2

Round Table A: Mental Health Futures – In Europe and Beyond

Facilitated by: Lars Münter

Thematic focus

How can mental health systems - across Europe and beyond - move from crisis response to genuine prevention and community resilience for our youth? What role do psychology, psychotherapy, health literacy, emotional competence, and cross-cultural knowledge exchange play in building the mental health infrastructure of 2050?

Scene-setting framings (7 minutes each)

Framing 1: EU-PROMENS perspective — insights from the multidisciplinary mental health training programme on what works across settings and populations; reflections on the Danish Training Programme with 200 sign-ups and 130 participants.

Framing 2: Cyprus Institute for Emotion-Focused Therapy (CiEFT) / ISEFT perspective — the evidence base for emotion-focused therapeutic approaches and how these can be embedded in community mental health systems at scale.

12:00 – 13:35 (Auditorium B) (75 min)

Session 3

Round Table B: Healthy Ageing - Global Knowledge sharing

Facilitated by: Lars Münter

Thematic focus

As populations across Europe and the Belt and Road age at unprecedented speed, how do we build health and care systems - and social environments - that support not just longer life, but genuinely flourishing later years? How do mental health, social connection, community design, and technology intersect in the ageing experience?

Scene-setting framings (7 minutes each)

Framing 1: NCIO perspective — the clinical and epidemiological dimensions of healthy ageing; multimorbidity, mental-physical health intersections, and the longevity economy.

Framing 2: Nordic Wellbeing Academy / EHFF perspective — systems and foresight framing; what does a 2050 healthy ageing society look like, and what governance and community architecture does it require?

GE HealthCare

14:30 – 16:00 **Session 4**
(Anatomy Room) **Creative Futures Session - Visualising Wellbeing 2050**

(90 min) Facilitated by: Nina Sønderberg

Concept
This session brings Round Table participants - still energised from their deliberative conversations - into smaller, mixed groups to co-create visual scenario posters depicting possible futures for mental health and healthy ageing. The method draws on established foresight and scenario-building practice, adapted for a group with diverse professional backgrounds and cultural perspectives.

Facilitation approach
Nina Sønderberg (Nordic Wellbeing Academy / European Health Futures Forum; member, WHO/Europe Public Health Innovation Platform) will lead this session. Nina has extensive experience in co-design processes, futures facilitation, and creative knowledge translation. She will guide groups through:

- A brief provocation - three possible worlds of 2050, presented as vivid narrative sketches (hopeful, cautionary, and wild-card)
- Small group formation - deliberately cross-disciplinary and cross-cultural
- Facilitated scenario building - each group selects or invents their future and begins mapping its key features: what do systems, communities, relationships, and daily life look like?
- Visual poster creation - groups translate their scenario into a large-format visual poster, combining text, image, and metaphor
- Gallery walk and sharing - posters are displayed; groups briefly present their future world; cross-pollination and reflection

Output
A set of 5–8 scenario posters produced by participants — bridging disciplines and perspectives. These will be photographed, digitised, and shared as a visual output of the day

PMI SCIENCE
PHILIP MORRIS INTERNATIONAL

4. FACILITATOR & ORGANISER PROFILES



(Round Tables A & B)

Lars Münter

International Director, Nordic Wellbeing Academy (NWA)
Network Director, European Health Futures Forum (EHFF)

Lars Münter is a health communication and systems leadership specialist with an H-index of 15 and 40+ publications. He chairs the WHO/Europe Public Health Innovation Platform Domain 4 working group on Public Health Communication & Trust (2026–2028), a 19-organisation group spanning 14 countries. He participated in the EU-PROMENS Exchange Programme in Barcelona and co-led the Danish EU-PROMENS Training Programme with 200 sign-ups and 130 participants. He facilitates the Round Tables in his capacity as International Director of NWA and Network Director of EHFF.



Creative Futures Session

Nina Sønderberg

National Director, Nordic Wellbeing Academy (NWA)
Director, European Health Futures Forum (EHFF)

Nina Sønderberg is a co-design and systems leadership specialist with deep expertise in creative facilitation and futures practice. She participated in the EU-PROMENS Exchange Programme in Barcelona and co-led the Danish EU-PROMENS Training Programme. She is a member of the WHO/Europe Public Health Innovation Platform. Nina will lead the Creative Futures Session, guiding participants through a foresight scenario-building process to produce scenario posters that bridge disciplines and geographies.



Main Track Session


Takis Kotis

Facilitator
IMBMC Main Track Session

Takis Kotis is a member of the WHO/Europe Public Health Innovation Platform and brings extensive experience in facilitating high-level interdisciplinary health dialogues. He will chair the Main Track Keynote Session, facilitating interaction between the five keynote speakers and the broader IMBMC audience, and will synthesise the session's key themes as a bridge to the Round Tables.

I.Patrikios
Founder and Chairman
Congress Scientific committee

Ioannis Patrikios



ENERGON
energon.com.cy

ENERGON



Sectra Education Portal and Table

SECTRA EDUCATION PORTAL

By connecting to Sectra Education Portal, a cloud-based sharing portal, teachers and students have access to an extensive library of cases, providing them with a wide variety of clinical content. Through Sectra's collaborative network, institutions can share cases and knowledge with other Sectra users from around the world.

THE SECTRA TABLE

Sectra Table is a multi-touch screen for interactive learning and teaching. It comes with an anatomy atlas and model cases (a number of pre-prepared clinical cases based on medical images), but you can easily add your own cases. Sectra's offering also includes a workspace for advanced preparation and organization of cases.

ENERGON

ENERGON

En-Ergon Scientific EES Ltd
T: +357 22 021 010
F: +357 22 780 770
E: info@energon.com.cy
W: www.energon.com.cy



thermo scientific
Authorised Distributor

Gaumard®
Simulators for Health Care Education

omega BIO-TEK

VILBER
Smart Imaging

ISBN 978-9925-604-09-8